Why the study?
Does sacubitril/valsartan improve clinical outcomes in heart failure and reduce blood pressure in hypertension compared to standard ACE inhibitors or ARBs?
RCT (n=8,442)
Double-blind
1:1
Yes
Does sacubitril/valsartan improve clinical outcomes in heart failure and reduce blood pressure in hypertension compared to standard ACE inhibitors or ARBs?
Sacubitril/valsartan is a novel angiotensin receptor-neprilysin inhibitor that significantly reduces cardiovascular mortality and heart failure hospitalizations in HFrEF compared to enalapril.
Answers are grounded in this paper and cite their sources.
May support sacubitril/valsartan in HFrEF; leaves open its role versus ACEi/ARBs in hypertension.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The December 2015 monograph topics are rolapitant, insulin degludec, flibanserin, coagulation factor IX (recombinant), and grazoprevir/elbasvir. The Safety MUE is on rolapitant.
No takes yet. Share an insight, caveat, or question.
Cada et al. (2015) conducted an RCT in Heart failure with reduced ejection fraction (n=8,442). Sacubitril/Valsartan vs. Enalapril 10 mg twice daily was evaluated on Composite outcome of death from cardiovascular causes or hospitalization for heart failure (HR 0.8, 95% CI 0.73 to 0.87, p=<.001).
Synapse has enriched 10 related papers. Consider them for comparative context: